Abstract
We report the time course of neutralizing antibody (NtAb) response, as measured by authentic virus neutralization, in healthcare workers (HCWs) with a mild or asymptomatic SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection diagnosed at the onset of the pandemic, with no reinfection throughout and after a three-dose schedule of the BNT162b2 mRNA vaccine with an overall follow-up of almost two years since infection. Forty-eight HCWs (median age 47 years, all immunocompetent) were evaluated: 29 (60.4%) were asymptomatic. NtAb serum was titrated at eight subsequent time points: T1 and T2 were after natural infection, T3 on the day of the first vaccine dose, T4 on the day of the second dose, T5, T6, and T7 were between the second and third dose, and T8 followed the third dose by a median of 34 days. NtAb titers at all postvaccination time points (T4 to T8) were significantly higher than all those at prevaccination time points (T1 to T3). The highest NtAb increase was following the first vaccine dose while subsequent doses did not further boost NtAb titers. However, the third vaccine dose appeared to revive waning immunity. NtAb levels were positively correlated at most time points suggesting an important role for immunogenetics.
Subject
Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology
Reference35 articles.
1. Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences
2. Tracking SARS-CoV-2 Variants
www.who.int/en/activities/tracking-SARS-CoV-2-variants
3. SARS-CoV-2 Delta Variant Now Dominant in Much of European Region; Efforts Must Be Reinforced to Prevent Transmission, Warns WHO Regional Office for Europe and ECDC
www.euro.who.int/en/media-centre/sections/press-releases/2021/sars-cov-2-delta-variant-now-dominantin-much-of-european-region-efforts-must-be-reinforced-toprevent-transmission,-warns-who-regional-office-foreuropeand-ecdc
4. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern
www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variantof-concern
5. A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson;Patel;Hum. Vaccin. Immunother.,2022
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献